Definium Therapeutics Reports Positive Phase 3 Results for DT120 ODT in Major Depressive Disorder

summarizeSummary

Definium Therapeutics announced highly positive topline results from its Phase 3 EMERGE study of DT120 ODT for Major Depressive Disorder, meeting all primary and key secondary endpoints with rapid and durable efficacy and a favorable safety profile.

check_boxKey Events

• Positive Phase 3 EMERGE Study Results

  Definium Therapeutics announced positive topline data from its Phase 3 EMERGE study of DT120 ODT for Major Depressive Disorder (MDD), meeting its primary and all key secondary efficacy endpoints.

• Significant Efficacy in MDD

  The study showed an 8.1 point placebo-adjusted change from baseline in MADRS total score at Week 6 (primary endpoint, p<0.0001) and a 7.3 point change at Week 12 (secondary endpoint, p<0.0001), demonstrating rapid and durable relief.

• Favorable Safety Profile

  DT120 ODT was generally well tolerated, with 99% of adverse events being mild to moderate. No serious adverse events or suicidality signals were identified.

• Efficient Dosing Session

  The average time for participants to clear the End of Session Checklist (EoSC) was 5.8 hours, with all participants clearing by 8 hours, supporting its potential for clinical practice.

auto_awesomeAnalysis

Definium Therapeutics announced highly positive topline results from its Phase 3 EMERGE study for DT120 ODT in Major Depressive Disorder (MDD). The drug met all primary and key secondary efficacy endpoints, demonstrating rapid, robust, and durable relief. This is a critical de-risking event for the company, validating its lead asset in a large market with significant unmet needs. The favorable safety profile and efficient dosing session further enhance its commercial potential, positioning DT120 ODT as a potential best-in-class treatment and a new paradigm for MDD management. This news, coming as the stock trades near its 52-week high, reinforces strong investor confidence in the company's pipeline.